Loading
An MRI dye given into a vein for scans of the brain and spine, used for example to show brain tumours and metastases.
Guerbet's Dotarem (NDA 204781, first approved 20 March 2013) is indicated "for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity". GE Healthcare's Clariscan is an approved generic (ANDA 210016, 1 November 2019) with the same indication. ATC V08CA02 (gadoteric acid). Like every gadolinium-based contrast agent in the United States, its label carries a boxed warning on the risks of intrathecal use and nephrogenic systemic fibrosis, a thickening of skin and organs seen in people with severe kidney disease.
A gadolinium chelate that brightens tissue on MRI where it leaves the blood, showing areas with a disrupted blood-brain barrier or abnormal vessels.
| Region | Year | Indication |
|---|---|---|
| US | 2013 | MRI of the brain, spine and associated tissues to visualise areas with disrupted blood-brain barrier or abnormal vascularity · NDA 204781; Guerbet |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Gadoterate meglumine" OR ABSTRACT:"Gadoterate meglumine" OR TITLE:"Dotarem" OR ABSTRACT:"Dotarem" OR TITLE:"gadoterate" OR ABSTRACT:"gadoterate" OR TITLE:"gadoteric acid" OR ABSTRACT:"gadoteric acid" OR TITLE:"Clariscan" OR ABSTRACT:"Clariscan") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gadoterate meglumine, not a curated reading list.
Shares Guerbet, Gadolinium-based and other MRI contrast agents, MRI and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, Brain metastases (secondary brain tumours), MRI, Glioma & glioblastoma and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, GE HealthCare, Brain metastases (secondary brain tumours), MRI and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Guerbet, Gadolinium-based and other MRI contrast agents, MRI, Glioma & glioblastoma and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, Brain metastases (secondary brain tumours), MRI, Glioma & glioblastoma and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, GE HealthCare, MRI and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, Brain metastases (secondary brain tumours), MRI, Glioma & glioblastoma and the tags contrast-agents-gaps-2026-11, diagnostic.
Shares Gadolinium-based and other MRI contrast agents, GE HealthCare, MRI and the tags contrast-agents-gaps-2026-11, diagnostic.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/